Vulval lichen sclerosus: An Australasian management consensus.
consensus
lichen sclerosus
management
recommendations
vulva
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
15
02
2021
received:
28
01
2021
accepted:
27
02
2021
pubmed:
13
6
2021
medline:
11
1
2022
entrez:
12
6
2021
Statut:
ppublish
Résumé
Vulval lichen sclerosus (VLS) is a chronic inflammatory skin condition predominantly affecting the anogenital region in women and children. To date, there is lack of agreement amongst experts on a severity scale to aid assessment, research and treatment stratification on VLS. Furthermore, literature on best practice for long-term management of VLS is lacking. The aim of this consensus is to provide broad guidelines on the short and long-term management of VLS. An initial focus group of Australasian experts in vulval dermatology developed a draft consensus statement for the management of VLS. Based on the results of the draft statement, a consensus panel of 22 Australasian experts, comprised of the initial and additional members, participated in an anonymous four-stage eDelphi process. Round 1 involved generation and voting on statements from the draft consensus statement developed by the focus group. In Rounds 2, 3 & 4, panel members were presented formal feedback from previous rounds and asked to indicate their level of agreement. Consensus was reached if there was ≥70% agreement on the importance of an item in the 4 (agree) to 5 (strongly agree) range. The expert panel, with a total of 504 collective years of experience in the field of VLS, reached consensus on a core set of 51 management statements related to diagnosis, severity, initial and long-term management, follow-up, and complications of VLS. This study has identified a set of management statements for VLS that may be useful in clinical practice in the Australasian population.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Vulval lichen sclerosus (VLS) is a chronic inflammatory skin condition predominantly affecting the anogenital region in women and children. To date, there is lack of agreement amongst experts on a severity scale to aid assessment, research and treatment stratification on VLS. Furthermore, literature on best practice for long-term management of VLS is lacking. The aim of this consensus is to provide broad guidelines on the short and long-term management of VLS.
METHODS
METHODS
An initial focus group of Australasian experts in vulval dermatology developed a draft consensus statement for the management of VLS. Based on the results of the draft statement, a consensus panel of 22 Australasian experts, comprised of the initial and additional members, participated in an anonymous four-stage eDelphi process. Round 1 involved generation and voting on statements from the draft consensus statement developed by the focus group. In Rounds 2, 3 & 4, panel members were presented formal feedback from previous rounds and asked to indicate their level of agreement. Consensus was reached if there was ≥70% agreement on the importance of an item in the 4 (agree) to 5 (strongly agree) range.
RESULTS
RESULTS
The expert panel, with a total of 504 collective years of experience in the field of VLS, reached consensus on a core set of 51 management statements related to diagnosis, severity, initial and long-term management, follow-up, and complications of VLS.
CONCLUSIONS
CONCLUSIONS
This study has identified a set of management statements for VLS that may be useful in clinical practice in the Australasian population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
292-299Informations de copyright
© 2021 The Australasian College of Dermatologists.
Références
Fischer GO. The commonest causes of symptomatic vulvar disease: a dermatologist's perspective. Australas. J. Dermatol. 1996; 37: 12-8.
Van de Nieuwenhof HP, Meeuwis KA, Nieboer TE et al. The effect of vulvar lichen sclerosus on quality of life and sexual functioning. J. Psychosom. Obstet. Gynaecol. 2010; 31: 279-84.
Lee A, Fischer G. Diagnosis and treatment of vulvar lichen sclerosus: an update for dermatologists. Am. J. Clin. Dermatol. 2018; 19: 695-706.
Kirtschig G, Cooper S, Aberer W et al. Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus. J. Eur. Acad. Dermatol. Venereol. 2017; 31: e81-e83.
Bleeker MCG, Visser PJ, Overbeek LIH et al. Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2016; 25: 1224-30.
Micheletti L, Preti M, Radici G et al. Vulvar Lichen sclerosus and neoplastic transformation: a retrospective study of 976 cases. J. Low Genit. Tract Dis. 2016; 20: 180-3.
Day T, Marzol A, Pagano R et al. Clinicopathologic diagnosis of differentiated vulvar intraepithelial neoplasia and vulvar aberrant maturation. J. Low Genit. Tract Dis. 2020; 24: 392-8.
Lewis FM, Tatnall FM, Velangi SS et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br. J. Dermatol. 2018; 178: 839-53.
Lee A, Bradford J, Fischer G. Evidence-based (S3) guideline on (anogenital) lichen sclerosus. JEADV. 2015; 29(10):e1-e43. J. Eur. Acad. Dermatol. Venereol. 2017; 31: e57-e58.
Jones RW, Scurry J, Neill S et al. Guidelines for the follow-up of women with vulvar lichen sclerosus in specialist clinics. Am. J. Obstet. Gynecol. 2008; 198: 496.e1-496.e3.
Bradford J, Fischer G. Long-term management of vulval lichen sclerosus in adult women. Aust. N. Z. J. Obstet. Gynaecol. 2010; 50: 148-52.
Keeney S, McKenna H, Hasson F. The Delphi Technique in Nursing and Health Research. Oxford: John Wiley & Sons, Inc. 2010; 208 p.
Gerbens LA, Boyce AE, Wall D et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. Trials. 2017; 18: 87.
Burden-Teh E, Thomas KS, Gran S et al. Development of clinical diagnostic criteria for plaque psoriasis in children: an electronic Delphi consensus study with the International Psoriasis Council. Br. J. Dermatol. 2019; 181: 856-7.
Holloway K. Doing the E-Delphi: using online survey tools. Comput. Inform. Nurs. 2012; 30: 347-50.
Saunderson RB, Harris V, Yeh R et al. Vulvar quality of life index (VQLI) - A simple tool to measure quality of life in patients with vulvar disease. Australas J. Dermatol. 2020; 61: 152-7.
Dalziel KL, Wojnarowska F. Long-term control of vulval lichen sclerosus after treatment with a potent topical steroid cream. J. Reprod. Med. 1993; 38: 25-7.
Chi CC, Kirtschig G, Baldo M et al. Topical interventions for genital lichen sclerosus. Cochrane Database Syst. Rev. 2011:CD008240.
Virgili A, Borghi A, Minghetti S et al. Mometasone fuoroate 0.1% ointment in the treatment of vulvar lichen sclerosus: a study of efficacy and safety on a large cohort of patients. J. Eur. Acad. Dermatol. Venereol. 2014; 28: 943-8.
Virgili A, Borghi A, Toni G et al. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. Br. J. Dermatol. 2014; 171: 388-96.
Nguyen Y, Bradford J, Fischer G. Lichen sclerosus in pregnancy: A review of 33 cases. Aust. N. Z. J. Obstet. Gynaecol. 2018; 58: 686-9.
Lee A, Bradford J, Fischer G. Long-term Management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol. 2015; 151: 1061-7.
Wijaya M, Lee G, Fischer G, Lee A. Quality of life in vulvar lichen sclerosus patients treated with long-term topical corticosteroids. J. Low. Genit. Tract. Dis. 2021; 25: 158-65.
Cooper SM, Gao XH, Powell JJ et al. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch. Dermatol. 2004; 140: 702-6.
Lorenz B, Kaufman RH, Kutzner SK. Lichen sclerosus. Therapy with clobetasol propionate. J. Reprod. Med. 1998; 43: 790-4.
Ellis E, Fischer G. Prepubertal-onset vulvar lichen sclerosus: the importance of maintenance therapy in long-term outcomes. Pediatr. Dermatol. 2015; 32: 461-7.
Balasubramaniam P, Lewis FM. Long-term follow-up of patients with lichen sclerosus: does it really happen? J. Obstet. Gynaecol. 2007; 27: 282.
Goldstein AT, Creasey A, Pfau R et al. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J. Am. Acad. Dermatol. 2011; 64: e99-104.
Fischer G, Bradford J. Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report. J. Reprod. Med. 2007; 52: 329-31.
Corazza M, Borghi A, Minghetti S et al. Clobetasol propionate vs. mometasone furoate in 1-year proactive maintenance therapy of vulvar lichen sclerosus: results from a comparative trial. J. Eur. Acad. Dermatol. Venereol. 2016; 30: 956-61.